Pharming Group N.V. Sponsored ADR

PHAR Healthcare Biotechnology

Pharming Group N.V. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $376.1 million, up 26.6% from fiscal 2024. In the quarter to June 2026, revenue fell 3.22%, EPS fell 57.1%, free cash flow fell 183.9% and total debt rose 1.55%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

9.36 0.27 −2.80%
Market cap
$681.6M
P/E
62.4×
Fwd P/E
0.0×
Dividend yield
—
F-score
5/9
Altman Z
3.88
Beneish M
−2.78
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
7 5 5 7

+8 more TTM periods

ROE
3.67% 5.10% 1.14% 0.12%
ROA
2.05% 2.77% 0.63% 0.06%
ROIC
5.50% 8.88% 8.27% 8.36%
Return on Tangible Assets
4.83% 6.50% 1.49% 0.15%
Average Days of Receivables
56.75 59.31 53.08 43.93
Free Cash Flow per Share
0.64 0.75 0.78 0.77
Free Cash Flow
34.37 55.72 53.95 52.71
Other line items

Show all line items

Columns are period end dates